Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00003597

NCT00003597
Completed Phase 1 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with a solid tumour (such as a sarcoma, kidney tumour, brain tumour, germ cell tumour, melanoma, retinoblastoma, or liver tumour) that has been confirmed by a tissue sample — except for brain stem tumours, which may be included without this (confirm with trial site)
  • Your cancer has come back or stopped responding to standard first-line treatment, and this recurrence happened within the last 4 weeks
  • You are between 1 and 21 years old
  • You are reasonably active and able to carry out daily activities, as measured by a standard health scale (confirm with trial site)
  • You are expected to live for at least 12 weeks
  • Your blood cell counts are at healthy enough levels — specifically, your infection-fighting cells and platelets are above certain thresholds (confirm with trial site)
  • Your liver is functioning within acceptable limits based on blood tests
  • Your kidneys are filtering blood well enough (at a rate of at least 70 mL/min)
  • Your heart is functioning normally, with no untreated irregular heartbeats and a healthy pumping ability
  • You are not currently pregnant or breastfeeding

Who may not be able to join:

  • Your cancer has spread to the bone marrow
  • You have had or currently have a type of blood cancer called myelogenous leukaemia
  • You have received certain blood cell-stimulating medications (colony-stimulating factors) within the last 10 days
  • You have received a medication called epoetin alfa (a red blood cell booster) within the last 30 days
  • You have received chemotherapy within the last 3 weeks (or within the last 6 weeks if it included a type called nitrosoureas)
  • You have received specific chemotherapy drugs (etoposide, carboplatin, or ifosfamide — the same ones used in this trial) within the last 3 months
  • You have previously had radiation therapy to the brain or spine
  • You have previously had radiation therapy covering more than half of your bone marrow
  • You have had significant blood clotting problems (grade III or IV thrombosis) (confirm with trial site)
  • You are currently taking lithium, aspirin, warfarin (coumadin), or heparin (blood-thinning or mood-stabilising medications)
  • You are currently taking any other experimental treatments or immune-system-stimulating medications (cytokines), including epoetin alfa

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Children's Oncology Group
Registry
clinicaltrials_gov
Start date
1 November 1998
Est. completion
1 October 2004

Where this trial is recruiting

🇦🇺 Australia 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Determine the pharmacokinetics and toxicities associated with the administration of recombinant human thrombopoietin (rhTPO)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov